Since genomic profiling for all kinds of tumor hasbeen increased eventually, the overexpression of HER2 was identified inseveral tumor types, including cervical (2.2%), bladder (3.6%), salivary (3.9%), vaginal(3.6%), endometrial (3.4%) and colorectal cancers (1.3%). The gene discussed is ERBB2; the disease is neoplasm.